Holen Sie sich die Stockscreener-App
134.25
1.92%
-2.63
Handel nachbörslich:
134.14
-0.11
-0.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$136.88
Offen:
$136.85
24-Stunden-Volumen:
5.66M
Relative Volume:
0.82
Marktkapitalisierung:
$166.63B
Einnahmen:
$29.45B
Nettoeinkommen (Verlust:
$8.51B
KGV:
19.79
EPS:
6.7823
Netto-Cashflow:
$9.46B
1W Leistung:
-2.16%
1M Leistung:
-9.87%
6M Leistung:
+19.76%
1J Leistung:
+20.77%
1-Tages-Spanne:
$134.10
$137.47
1-Wochen-Bereich:
$134.10
$140.41
52-Wochen-Spanne:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
134.25 | 166.63B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
878.24 | 784.58B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.45 | 579.15B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.40 | 370.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.63 | 295.77B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
188.42 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences, Inc. $GILD Stake Lifted by USA Financial Formulas - MarketBeat
Wedge Capital Management L L P NC Reduces Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Synergy Asset Management LLC Has $204,000 Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Exchange Traded Concepts LLC Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks (NASDAQ:GILD) - Seeking Alpha
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today - Yahoo Finance
Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade) (GILD) - Seeking Alpha
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Daniel O'Day sells shares at Gilead Sciences (NASDAQ: GILD) - Stock Titan
Gilead Sciences Inc Stock: Strong HIV Franchise and Dividend Growth Position Shares for Long-Term Va - AD HOC NEWS
Deutsche Bank reiterates Buy on Gilead Sciences stock, $155 target - Investing.com
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook? - TradingView
Gilead Sciences FY2026 EPS Increased by Erste Group Bank - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Global X Japan Co. Ltd. - MarketBeat
Rx Rundown: Merck, Gilead Sciences and Sanofi and more - Medical Marketing and Media
NatWest Group plc Has $5.40 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences nears $2B deal for Ouro MedicinesFT - MSN
Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline - Insider Monkey
Gilead Sciences stock consolidates as executive spotlights new HIV prevention development approach - Traders Union
Vanguard disaggregates holdings; GILD reporting shows 0 shares (Vanguard) - Stock Titan
Gilead Sciences Inc (XSWX:GILD) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
The Unprecedented Role Manufacturing Innovation Played in Shaping Gilead’s Long-Acting HIV Prevention Therapy - Gilead Sciences
SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts - GlobeNewswire Inc.
Czech National Bank Buys 12,009 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Assenagon Asset Management S.A. Has $32.78 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences stock surges on double blockbuster announcement amid biotech rally - AD HOC NEWS
Gilead Sciences stock surges on double blockbuster announcements amid biotech rally - AD HOC NEWS
Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports - AOL.com
Gilead Acquires Ouro Medicines for $2.18B to Boost Autoimmune Pipeline | 2026News and Statistics - IndexBox
Scotiabank Reaffirms Their Buy Rating on Gilead Sciences (GILD) - The Globe and Mail
Pensionfund Sabic Takes $2.19 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More - BioSpace
Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition - Pharmaceutical Technology
Net income of Gilead Sciences from 2021 to 2025 - Statista
Gilead Eyes $2.2 Billion Autoimmune Push With Ouro Deal - GuruFocus
Market Today: Oil Rebounds; Disney Exits OpenAI Deal; Gilead Buys Ouro - GuruFocus
Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition - MedCity News
Clear Street reiterates Cullinan Oncology stock rating on Gilead deal validation - Investing.com
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition - Benzinga
Gilead Sciences Inc and Arcus Biosciences Inc Post ARC-7 Plenary Q&A Transcript - GuruFocus
Gilead Expands Into Autoimmune With Ouro Deal And Galapagos Alliance - simplywall.st
Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout - Pharmaceutical Technology
Gilead’s $2.2bn buy of Ouro Medicines includes Galapagos alliance - BioXconomy
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases - BioPharma Dive
Gilead acquires potential first-in-class T cell engager in $2bn deal with Ouro Medicines - European Pharmaceutical Review
Gilead pens dual-purpose $2B Ouro M&A deal with Galapagos - BioWorld MedTech
Gilead inks Manta pact to dive deeper into cancer patient aid - Fierce Pharma
Gilead Sciences Enters $2.1 Billion Definitive Agreement to Acquire Ouro Medicines - Pharmaceutical Executive
Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. - Barron's
Gilead Sciences buys Ouro Medicines in deal worth up to $2.18 billion - Новости GxP
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.99%
2.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):